Table 3 Differential provision of artemisinin-based drugs by different healthcare providers
| Â | Patent Medicine Dealer n = 860 n (%) | PHC centre n = 273 n (%) | Public Hospital n = 195 n (%) | Pharmacy n = 222 n (%) | Private hospital n = 716 n (%) | Laboratory n = 38 n (%) | Chi-square (p-value) |
|---|---|---|---|---|---|---|---|
Drugs prescribed | Â | Â | Â | Â | Â | Â | Â |
AS monotherapy | 43 (5.2) | 6(2.2) | 5 (2.6) | 27(7.5) | 84 (6.1) | 2 (5.2) | 45.2 (.0001) |
ACT | 5 (0.6) | 1(0.4) | 15(7.7) | 7 (3.2) | 10 (1.4) | 0 (0) | 56.4 (.0001) |
Drugs procured | Â | Â | Â | Â | Â | Â | Â |
AS monotherapy | 44 (5.2) | 5(1.8) | 16 (8.2) | 26 (11.7) | 76 (10.6) | 0 (0) | 58.3 (.0001) |
ACT | 8 (0.9) | 0(0) | 15 (7.7) | 9 (4.1) | 10 (1.4) | 1 (2.6) | 36.4 (.0001) |